Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

Brown, S; Everett, CC; Naraghi, K; Davies, C; Dawkins, B; Hulme, C; McCabe, C; Pavitt, S; Emery, P; Sharples, L; +1 more... Buch, MH; (2018) Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Technical Report. NIHR Journals Library. DOI: https://doi.org/10.3310/hta22340

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.3310/hta22340

Abstract

Share

Download

Filename: Alternative-tumour-necrosis-factor-inhibitors-TNFi.pdf

Licence: Copyright the publishers

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar